BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37843751)

  • 1. Multicenter prospective phase II trial of concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with advanced head and neck squamous cell carcinoma.
    Ueki Y; Ohshima S; Yokoyama Y; Takahashi T; Shodo R; Yamazaki K; Ohtaki K; Saijo K; Tanaka R; Togashi T; Sato Y; Takano S; Omata J; Takahashi N; Okabe R; Horii A
    Int J Clin Oncol; 2024 Jan; 29(1):20-26. PubMed ID: 37843751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
    Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
    Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.
    Mizumachi T; Homma A; Kakizaki T; Sakashita T; Kano S; Hatakeyama H; Tsuchiya K; Yasuda K; Onimaru R; Shirato H; Taguchi J; Shimizu Y; Kinoshita I; Akita H; Fukuda S
    Int J Clin Oncol; 2015 Jun; 20(3):431-7. PubMed ID: 24993675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
    Enokida T; Ogawa T; Homma A; Okami K; Minami S; Nakanome A; Shimizu Y; Maki D; Ueda Y; Fujisawa T; Motegi A; Ohkoshi A; Taguchi J; Ebisumoto K; Nomura S; Okano S; Tahara M
    Cancer Med; 2020 Mar; 9(5):1671-1682. PubMed ID: 31943834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective phase II randomized study of docetaxel combined with lobaplatin versus TPF regimen induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.
    Zhang M; Chen Y; Wu W; Jin F; Li Y; Long J; Luo X; Gong X; Chen X; Liu L; Tang H; Wang Z
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):18081-18091. PubMed ID: 37985501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective pilot study of consolidation chemotherapy with docetaxel and cisplatin after concurrent chemoradiotherapy for advanced head and neck cancer.
    Lee KC; Lee SH; Lee Y; Park SH; Park J; Cho EK; Shin DB; Lee JH; Kim DY; Kim ST
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):187-91. PubMed ID: 17996392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx.
    Loong HH; Winquist E; Waldron J; Chen EX; Kim J; Palma D; Read N; Razak AR; Diaz-Padilla I; Chan K; Bayley A; Hossain M; Wang L; Chin S; Siu LL; Hope A
    Eur J Cancer; 2014 Sep; 50(13):2263-70. PubMed ID: 24953566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of concomitant chemoradiation in locally advanced head and neck cancers.
    Lasrado S; Moras K; Pinto GJ; Bhat M; Hegde S; Sathian B; Luis NA
    Asian Pac J Cancer Prev; 2014; 15(10):4147-52. PubMed ID: 24935361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter phase I/II study of chemoradiotherapy with high-dose CDDP for head and neck squamous cell carcinoma in Japan.
    Matsuyama H; Yamazaki K; Okabe R; Ueki Y; Shodo R; Omata J; Sato Y; Ota H; Takahashi T; Tomita M; Yokoyama Y; Togashi T; Aoyama H; Abe E; Saijo Y; Katsura K; Soga M; Sugita T; Matsumoto Y; Tsuchida E; Horii A
    Auris Nasus Larynx; 2018 Oct; 45(5):1086-1092. PubMed ID: 29567334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparison of acute toxicity in 2 treatment courses: Three-weekly and weekly cisplatin treatment administered with radiotherapy in patients with head and neck squamous cell carcinoma.
    Mackiewicz J; Rybarczyk-Kasiuchnicz A; Łasińska I; Mazur-Roszak M; Świniuch D; Michalak M; Kaźmierska J; Studniarek A; Krokowicz Ł; Bajon T
    Medicine (Baltimore); 2017 Dec; 96(51):e9151. PubMed ID: 29390445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of individualized/dynamic cisplatin regimens for definitive concurrent chemoradiation therapy in patients with head and neck squamous cell carcinoma.
    Ahn D; Lee GJ; Sohn JH; Lee JE
    Cancer Med; 2020 Dec; 9(24):9256-9265. PubMed ID: 33073917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
    Schwartz DL; Montgomery RB; Yueh B; Donahue M; Anzai Y; Canby R; Buelna R; Anderson L; Boyd C; Hutson J; Keegan K
    Cancer; 2005 Jun; 103(12):2534-43. PubMed ID: 15856475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
    Ghi MG; Paccagnella A; D'Amanzo P; Mione CA; Fasan S; Paro S; Mastromauro C; Carnuccio R; Turcato G; Gatti C; Pallini A; Nascimben O; Biason R; Oniga F; Medici M; Rossi F; Fila G
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):481-7. PubMed ID: 15145166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial.
    Rampino M; Ricardi U; Munoz F; Reali A; Barone C; Musu AR; Balcet V; Franco P; Grillo R; Bustreo S; Pecorari G; Cavalot A; Garzino Demo P; Ciuffreda L; Ragona R; Schena M
    Clin Oncol (R Coll Radiol); 2011 Mar; 23(2):134-40. PubMed ID: 21030225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.
    Specenier PM; Remenar E; Buter J; Schrijvers DL; Bergamini C; Licitra LF; Awada A; Clement PM; Fortpied C; Menis J; Vermorken JB
    Ann Oncol; 2017 Sep; 28(9):2219-2224. PubMed ID: 28911062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative chemoradiotherapy for high-risk head-and-neck squamous cell carcinoma.
    Porceddu SV; Campbell B; Rischin D; Corry J; Weih L; Guerrieri M; Grossi M; Peters LJ
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):365-73. PubMed ID: 15380568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
    Hamauchi S; Yokota T; Mizumachi T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H; Homma A
    Int J Clin Oncol; 2019 May; 24(5):468-475. PubMed ID: 30656463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
    Lee YG; Kang EJ; Keam B; Choi JH; Kim JS; Park KU; Lee KE; Kwon JH; Lee KW; Kim MK; Ahn HK; Shin SH; Kim HR; Kim SB; Yun HJ
    BMC Cancer; 2020 Aug; 20(1):813. PubMed ID: 32854649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant chemoradiotherapy using carboplatin, tegafur-uracil and leucovorin for stage III and IV head-and-neck cancer: results of GORTEC Phase II study.
    Fesneau M; Pointreau Y; Chapet S; Martin L; Pommier P; Alfonsi M; Laguerre B; Feham N; Berger C; Garaud P; Calais G
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):154-63. PubMed ID: 19386430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.